MJ Biz Reports Australia To Expedite Epidiolex
This is what they are saying post the Senate hearing on Wednesday The only medical cannabis product in the Australian Register of Therapeutic Goods might soon be joined by another. Australian health regulators quietly gave Epidiolex, a cannabidiol medication, orphan designation and priority review status in late 2019. The designations allow the Therapeutic Goods Administration to wave application and evaluation fees, as well as expediting its assessment of the application to list Epidiolex in the ARTG, the Department of Health disclosed in a recent public submission to a Senate committee. Australia expedites review of medical cannabis product Epidiolex
Excerpt only …
READ MORE BELOW
Source : CANNANNEW REPORT
Link to original : MJ Biz Reports Australia To Expedite Epidiolex
reposted by Cannabis News World
You must log in to post a comment.